Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912297541> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W2912297541 abstract "Introduction: Direct oral anticoagulants (DOACs) are increasingly used as alternatives to warfarin for secondary prevention in ischemic stroke patients with atrial fibrillation. Despite demonstrated efficacy in clinical trials, there are few real-world experiences of DOACs vs. warfarin in community practice. Methods: We analyzed ischemic stroke survivors with atrial fibrillation discharged from the Get With The Guidelines Stroke hospitals between 2011-2014 and linked to Medicare claims for longitudinal outcomes through 2015. A propensity score overlap weighting method was used to compare DOACs vs. warfarin. The primary outcomes were major adverse cardiovascular events (MACE) and home time, a patient-centered outcome reflecting desire of “being alive at home, without recurrent stroke, or being hospitalized for complications.” Results: Among 11,662 stroke survivors (median age 80), 4,041 (34.7%) were discharged on DOACs (dabigatran, rivaroxaban, or apixaban) and 7,621 on warfarin. Except for NIHSS (median 4 [IQR 1-9] vs. 5 [2-11]), baseline demographics, medical history, and clinical characteristics were similar between two cohorts. Compared with warfarin, patients discharged on DOACs were less likely to experience MACE (33.95% vs. 40.36% per year, adjusted hazard ratio 0.89, 99% CI 0.83-0.96) and had more days at home (mean 287 vs. 263 days during the first year post discharge, adjusted difference 15.6 days, 99% CI 9.0-22.1) ( Table ). Additionally, there were fewer deaths, all-cause readmissions, cardiovascular readmissions, hemorrhagic strokes, and bleeding hospitalizations in DOAC-treated patients, although no significant differences in fatal bleeding, ischemic stroke readmission, systemic embolism, pneumonia, or sepsis (two negative outcome controls) between the two cohorts. Conclusions: In ischemic stroke survivors with atrial fibrillation, DOACs were associated with improved long-term clinical outcomes compared with warfarin." @default.
- W2912297541 created "2019-02-21" @default.
- W2912297541 creator A5005116549 @default.
- W2912297541 creator A5010571732 @default.
- W2912297541 creator A5011876917 @default.
- W2912297541 creator A5012849300 @default.
- W2912297541 creator A5015783013 @default.
- W2912297541 creator A5020723643 @default.
- W2912297541 creator A5035264987 @default.
- W2912297541 creator A5038555027 @default.
- W2912297541 creator A5042180486 @default.
- W2912297541 creator A5043643766 @default.
- W2912297541 creator A5064002558 @default.
- W2912297541 creator A5070062505 @default.
- W2912297541 creator A5070928171 @default.
- W2912297541 creator A5083429631 @default.
- W2912297541 creator A5086804502 @default.
- W2912297541 creator A5088527297 @default.
- W2912297541 creator A5091109076 @default.
- W2912297541 date "2019-02-01" @default.
- W2912297541 modified "2023-09-27" @default.
- W2912297541 title "Abstract WMP85: Clinical Effectiveness of Direct Oral Anticoagulants (DOACs) vs. Warfarin in Older Ischemic Stroke Patients With Atrial Fibrillation: Findings From Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study" @default.
- W2912297541 doi "https://doi.org/10.1161/str.50.suppl_1.wmp85" @default.
- W2912297541 hasPublicationYear "2019" @default.
- W2912297541 type Work @default.
- W2912297541 sameAs 2912297541 @default.
- W2912297541 citedByCount "0" @default.
- W2912297541 crossrefType "journal-article" @default.
- W2912297541 hasAuthorship W2912297541A5005116549 @default.
- W2912297541 hasAuthorship W2912297541A5010571732 @default.
- W2912297541 hasAuthorship W2912297541A5011876917 @default.
- W2912297541 hasAuthorship W2912297541A5012849300 @default.
- W2912297541 hasAuthorship W2912297541A5015783013 @default.
- W2912297541 hasAuthorship W2912297541A5020723643 @default.
- W2912297541 hasAuthorship W2912297541A5035264987 @default.
- W2912297541 hasAuthorship W2912297541A5038555027 @default.
- W2912297541 hasAuthorship W2912297541A5042180486 @default.
- W2912297541 hasAuthorship W2912297541A5043643766 @default.
- W2912297541 hasAuthorship W2912297541A5064002558 @default.
- W2912297541 hasAuthorship W2912297541A5070062505 @default.
- W2912297541 hasAuthorship W2912297541A5070928171 @default.
- W2912297541 hasAuthorship W2912297541A5083429631 @default.
- W2912297541 hasAuthorship W2912297541A5086804502 @default.
- W2912297541 hasAuthorship W2912297541A5088527297 @default.
- W2912297541 hasAuthorship W2912297541A5091109076 @default.
- W2912297541 hasConcept C126322002 @default.
- W2912297541 hasConcept C127413603 @default.
- W2912297541 hasConcept C164705383 @default.
- W2912297541 hasConcept C194828623 @default.
- W2912297541 hasConcept C207103383 @default.
- W2912297541 hasConcept C2776301958 @default.
- W2912297541 hasConcept C2778661090 @default.
- W2912297541 hasConcept C2778810321 @default.
- W2912297541 hasConcept C2779161974 @default.
- W2912297541 hasConcept C2780290652 @default.
- W2912297541 hasConcept C2780400711 @default.
- W2912297541 hasConcept C2780638905 @default.
- W2912297541 hasConcept C2780645631 @default.
- W2912297541 hasConcept C2780739214 @default.
- W2912297541 hasConcept C44249647 @default.
- W2912297541 hasConcept C500558357 @default.
- W2912297541 hasConcept C71924100 @default.
- W2912297541 hasConcept C78519656 @default.
- W2912297541 hasConceptScore W2912297541C126322002 @default.
- W2912297541 hasConceptScore W2912297541C127413603 @default.
- W2912297541 hasConceptScore W2912297541C164705383 @default.
- W2912297541 hasConceptScore W2912297541C194828623 @default.
- W2912297541 hasConceptScore W2912297541C207103383 @default.
- W2912297541 hasConceptScore W2912297541C2776301958 @default.
- W2912297541 hasConceptScore W2912297541C2778661090 @default.
- W2912297541 hasConceptScore W2912297541C2778810321 @default.
- W2912297541 hasConceptScore W2912297541C2779161974 @default.
- W2912297541 hasConceptScore W2912297541C2780290652 @default.
- W2912297541 hasConceptScore W2912297541C2780400711 @default.
- W2912297541 hasConceptScore W2912297541C2780638905 @default.
- W2912297541 hasConceptScore W2912297541C2780645631 @default.
- W2912297541 hasConceptScore W2912297541C2780739214 @default.
- W2912297541 hasConceptScore W2912297541C44249647 @default.
- W2912297541 hasConceptScore W2912297541C500558357 @default.
- W2912297541 hasConceptScore W2912297541C71924100 @default.
- W2912297541 hasConceptScore W2912297541C78519656 @default.
- W2912297541 hasIssue "Suppl_1" @default.
- W2912297541 hasLocation W29122975411 @default.
- W2912297541 hasOpenAccess W2912297541 @default.
- W2912297541 hasPrimaryLocation W29122975411 @default.
- W2912297541 hasRelatedWork W1972269502 @default.
- W2912297541 hasRelatedWork W2006773714 @default.
- W2912297541 hasRelatedWork W2328164780 @default.
- W2912297541 hasRelatedWork W2372279560 @default.
- W2912297541 hasRelatedWork W2912297541 @default.
- W2912297541 hasRelatedWork W2990629389 @default.
- W2912297541 hasRelatedWork W3016213733 @default.
- W2912297541 hasRelatedWork W3173880122 @default.
- W2912297541 hasRelatedWork W3197429252 @default.
- W2912297541 hasRelatedWork W4319019627 @default.
- W2912297541 hasVolume "50" @default.
- W2912297541 isParatext "false" @default.
- W2912297541 isRetracted "false" @default.
- W2912297541 magId "2912297541" @default.
- W2912297541 workType "article" @default.